AI assistant
NovoCure Ltd — Director's Dealing 2026
Mar 3, 2026
31949_dirs_2026-03-03_b9a7245a-e3d5-4ac0-a1b7-827b651e1711.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2026-02-27
Reporting Person: Paravasthu Mukund (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-02-27 | Ordinary Shares | S | 1555.00 | $13.6638 | Disposed | 76751.00 | Direct |
| 2026-03-02 | Ordinary Shares | S | 408.00 | $13.493 | Disposed | 76343.00 | Direct |
Footnotes
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: This transaction was executed in multiple trades at prices ranging from $13.45 USD to $13.97 USD; the price reported above reflects the weighted average sale price.
F3: This transaction was executed in multiple trades at prices ranging from $13.3126 USD to $13.70 USD; the price reported above reflects the weighted average sale price.